EZH2 and prostate cancer: Nonetheless, our findings support the observed overexpression of Ezh2 in breast and prostate cancer [19], as DUT145, a prostatic adenocarcinoma, was observed to exhibit significant overexpression of Ezh2.2 (Figure 1) and belongs to the cluster of tissues with elevated H3K27me3 levels (Figure 3).Our ability to specify combinatorial modifications using mass spectrometry provides a dimension of the data that is nearly intractable from previous reports yet is an important consideration especially for the design of pharmacological inhibitors.